Skip to main navigation Skip to search Skip to main content

Targeted lung cancer screening selects individuals at high risk of cardiovascular disease.

  • Haval Balata
  • , Sean Knight
  • , P Barber
  • , D Colligan
  • , Emma Crosbie
  • , R Duerdan
  • , P Elton
  • , M Evison
  • , M Greaves
  • , J. Howells
  • , Klaus Irion
  • , D Karunaratne
  • , M Kirwan
  • , A. Macnab
  • , S Mellor
  • , Christopher Miller
  • , T Newton
  • , J Novasio
  • , R Sawyer
  • , A Sharman
  • K Slevin, E Smith, B Taylor, S. Taylor, J Tonge, A Walsham, S. Waplington, J. Whittaker, Richard Booton, Philip Crosbie

Research output: Contribution to journalArticlepeer-review

648 Downloads (Pure)

Abstract

Background: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in populations eligible for lung cancer screening. The aim of this study was to determine whether a brief CV risk assessment, delivered as part of a targeted community-based lung cancer screening programme, was effective in identifying individuals at high risk who might benefit from primary prevention. Methods: The Manchester Lung Screening Pilot consisted of annual low dose CT (LDCT) over 2 screening rounds, targeted at individuals in deprived areas at high risk of lung cancer (age 55-74 and 6- year risk ≥1.51%, using PLCOM2012 risk model). All participants of the second screening round were eligible to take part in the study. Ten-year CV risk was estimated using QRISK2 in participants without CVD and compared to age (±5 years) and sex matched Health Survey for England (HSE) controls; high risk was defined as QRISK2 score ≥10%. Coronary artery calcification (CAC) was assessed on LDCT scans and compared to QRISK2 score. Results: Seventy-seven percent (n=920/1,194) of screening attendees were included in the analysis; mean age 65.6±5.4 and 50.4% female. QRISK2 and lung cancer risk (PLCOM2012) scores were correlated (r=0.26, p<0.001). Median QRISK2 score was 21.1% (IQR 14.9-29.6) in those without established CVD (77.6%, n=714/920), double that of HSE controls (10.3%, IQR 6.6-16.2; n=714) (p<0.001). QRISK2 score was significantly higher in those with CAC (p<0.001). Screening attendees were 10-fold more likely to be classified high risk (OR 10.2 [95% CI 7.3-14.0]). One third (33.7%, n=310/920) of all study participants were high risk but not receiving statin therapy for primary CVD prevention. Discussion: Opportunistic CVD risk assessment within a targeted lung cancer screening programme is feasible and is likely to identify a very large number of individuals suitable for primary prevention.
Original languageEnglish
Pages (from-to)148-153
Number of pages6
JournalLung Cancer
Volume124
Early online date8 Aug 2018
DOIs
Publication statusPublished - Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Targeted lung cancer screening selects individuals at high risk of cardiovascular disease.'. Together they form a unique fingerprint.

Cite this